Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
BPC-157 vs Cartalax
An educational, source-based comparison of BPC-157 and Cartalax — how each peptide works, what it's researched for, and what to know before going deeper.
A pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Research suggests it modulates the nitric oxide system, upregulates growth hormone receptors in injured tissue, and promotes angiogenesis (formation of new blood vessels) — mechanisms associated with accelerated tendon, ligament, muscle, and intestinal mucosa repair in preclinical models.
- Tendon-to-bone healing
- Ligament and muscle recovery
- Gastric ulcer protection
- Inflammatory bowel models
- Neuroprotection (rodent)
- • Human clinical trials are limited — most research is preclinical.
- • Not FDA-approved for human therapeutic use.
- • Quality, purity, and dosing of compounded peptides vary widely.
Tripeptide bioregulator researched for cartilage and joint support.
A synthetic tripeptide (Ala-Glu-Asp) in the Khavinson short-peptide family. Research suggests gene-expression modulation in chondrocytes and fibroblasts, supporting extracellular matrix synthesis and reducing cartilage degradation markers.
- Osteoarthritis and cartilage repair
- Joint mobility in aging
- Tendon and ligament integrity
- • Preclinical and Russian clinical data only.
- • Not FDA-approved.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
3 cited studies; evidence base is growing.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| BPC-157 | Pentadecapeptide BPC 157 and the central nervous system | Neural Regeneration Research | 2022 | Review of neuroprotective and neurorepair signaling pathways observed in animal models. |
| BPC-157 | Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia/reperfusion in rats | Journal of Physiology - Paris | 2018 | Demonstrated mucosal protective effects and accelerated recovery from induced colitis. |
| BPC-157 | BPC 157 and tendon-to-bone healing | Journal of Orthopaedic Research | 2010 | Improved biomechanical recovery of transected Achilles tendons in rats. |
| Cartalax | Cartalax and chondrocyte gene expression | Bulletin of Experimental Biology and Medicine | 2015 | Modulated collagen type II and aggrecan expression in cultured chondrocytes. |
Side-effect & safety grid
- Human clinical trials are limited — most research is preclinical.
- Not FDA-approved for human therapeutic use.
- Quality, purity, and dosing of compounded peptides vary widely.
- Preclinical and Russian clinical data only.
- Not FDA-approved.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
BPC-157 vs Cartalax — Key differences
- Class: BPC-157 is classified as Tissue Repair · Gastrointestinal, while Cartalax is Musculoskeletal · Bioregulator.
- Primary research focus: BPC-157 — tendon-to-bone healing; Cartalax — osteoarthritis and cartilage repair.
- Tag: Recovery vs Joint · Bioregulator.
BPC-157 Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Tendon and ligament recovery (preclinical) | Rodent models (rat, mouse) | Subcutaneous or intraperitoneal | 10 mcg/kg/day | 10–14 days in most cited studies | Animal data only; cited human-grade safety or efficacy evidence is not established. |
| GI mucosal recovery (preclinical) | Rodent models | Oral or intragastric in some studies; subcutaneous in others | 10–50 mcg/kg/day depending on study | 5–14 days | Frequently cited in gut-recovery literature; remains preclinical. |
| Anecdotal human research-use (non-clinical literature) | Adults, mixed; off-label | Subcutaneous | Commonly cited 250–500 mcg, 1–2× daily | 2–6 week cycles in user reports | Not validated by controlled human trials; FDA has flagged BPC-157 outside approved drug pathways. |
BPC-157 Research — Female vs Male Studies
How published BPC-157 research breaks down by sex, including which populations were studied and what trial data exist.
Female research
Female-specific clinical trial data for BPC-157 are essentially absent. Preclinical rodent studies have included female animals but do not isolate sex-based outcomes.
- Female rodents in tissue-recovery models
- • No published human RCTs stratified by sex.
- • Pregnancy, lactation, and hormonal-cycle effects have not been characterized.
Male research
Male-specific clinical data are similarly limited. Most cited animal studies use male rodents for tendon, ligament, and GI models.
- Male rodents in tendon/ligament/GI repair models
- • No published human RCTs in men.
- • Anecdotal human use reports skew male but do not constitute clinical evidence.
BPC-157 — Frequently Asked Questions
Is BPC-157 FDA-approved?+
No. BPC-157 is not FDA-approved for any indication. It has appeared on the FDA's bulk-substance review lists as not eligible for traditional compounding under current evidence.
What does research suggest BPC-157 is studied for?+
Most cited BPC-157 research involves rodent models of tendon, ligament, and gastrointestinal mucosal recovery. Human controlled trial data remain very limited.
Are BPC-157 protocols the same for men and women?+
Published literature does not separate BPC-157 dosing by sex. There are no controlled human trials establishing sex-specific protocols.